See more : Asmo Corporation (2654.T) Income Statement Analysis – Financial Results
Complete financial analysis of Merck & Co., Inc. (MRK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Merck & Co., Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Eledon Pharmaceuticals, Inc. (ELDN) Income Statement Analysis – Financial Results
- Odyssey Group International, Inc. (ODYY) Income Statement Analysis – Financial Results
- Founder Securities Co., Ltd. (601901.SS) Income Statement Analysis – Financial Results
- Numinus Wellness Inc. (NUMI.TO) Income Statement Analysis – Financial Results
- Soulbrain Co., Ltd. (357780.KQ) Income Statement Analysis – Financial Results
Merck & Co., Inc. (MRK)
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.12B | 59.28B | 48.70B | 41.52B | 46.84B | 42.29B | 40.12B | 39.81B | 39.50B | 42.24B | 44.03B | 47.27B | 48.05B | 45.99B | 27.43B | 23.85B | 24.20B | 22.64B | 22.01B | 22.94B | 22.49B | 51.79B | 47.72B | 40.36B | 32.71B | 26.90B | 23.64B | 19.83B | 16.68B | 14.97B | 10.50B | 9.66B | 8.60B | 7.67B | 6.55B | 5.94B | 5.06B | 4.13B | 3.55B |
| Cost of Revenue | 16.13B | 17.41B | 13.63B | 13.62B | 14.11B | 13.51B | 12.78B | 13.89B | 14.93B | 16.77B | 16.95B | 16.45B | 16.87B | 18.40B | 9.02B | 5.58B | 6.14B | 6.00B | 5.15B | 4.96B | 4.32B | 33.05B | 28.98B | 21.17B | 16.71B | 13.17B | 10.95B | 8.59B | 6.79B | 5.28B | 2.11B | 1.77B | 1.67B | 1.52B | 1.33B | 1.32B | 1.23B | 1.14B | 1.09B |
| Gross Profit | 43.99B | 41.87B | 35.08B | 27.90B | 32.73B | 28.79B | 27.35B | 25.92B | 24.56B | 25.47B | 27.08B | 30.82B | 31.18B | 27.59B | 18.41B | 18.27B | 18.06B | 16.63B | 16.86B | 17.98B | 18.17B | 18.74B | 18.74B | 19.20B | 16.01B | 13.72B | 12.68B | 11.24B | 9.89B | 9.69B | 8.39B | 7.89B | 6.93B | 6.15B | 5.22B | 4.62B | 3.83B | 2.98B | 2.46B |
| Gross Profit Ratio | 73.17% | 70.63% | 72.02% | 67.20% | 69.87% | 68.06% | 68.16% | 65.10% | 62.19% | 60.30% | 61.50% | 65.21% | 64.89% | 60.00% | 67.12% | 76.59% | 74.62% | 73.49% | 76.61% | 78.38% | 80.81% | 36.18% | 39.27% | 47.56% | 48.93% | 51.02% | 53.66% | 56.69% | 59.30% | 64.72% | 79.89% | 81.63% | 80.57% | 80.13% | 79.72% | 77.76% | 75.61% | 72.29% | 69.28% |
| Research & Development | 30.53B | 13.55B | 12.25B | 13.40B | 9.87B | 9.75B | 9.98B | 7.19B | 6.70B | 7.18B | 7.50B | 8.17B | 8.47B | 10.99B | 5.85B | 4.81B | 4.88B | 4.78B | 3.85B | 4.01B | 3.18B | 2.68B | 2.46B | 2.34B | 2.07B | 1.82B | 1.68B | 1.49B | 1.33B | 1.23B | 1.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.20B | 7.84B | 7.63B | 7.16B | 8.72B | 8.00B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.30B | 2.20B | 2.00B | 1.80B | 1.90B | 2.10B | 9.83B | 9.76B | 10.31B | 11.61B | 11.91B | 12.78B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.50B | 10.04B | 9.63B | 8.96B | 10.62B | 10.10B | 9.83B | 9.76B | 10.31B | 11.61B | 11.91B | 12.78B | 13.73B | 13.25B | 8.54B | 7.38B | 7.56B | 8.17B | 7.16B | 7.35B | 6.39B | 6.19B | 6.22B | 6.17B | 5.20B | 4.51B | 4.30B | 3.84B | 3.30B | 3.18B | 2.91B | 4.07B | 3.56B | 3.24B | 2.76B | 2.55B | 2.25B | 1.75B | 1.33B |
| Other Expenses | 0.00 | 960.00M | 468.00M | 469.00M | -139.00M | 849.00M | 304.00M | -357.00M | -72.00M | 12.00B | 12.00M | 44.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 40.91B | 23.59B | 21.88B | 22.35B | 20.49B | 19.85B | 19.81B | 16.96B | 17.02B | 18.79B | 19.41B | 20.94B | 22.20B | 24.24B | 14.39B | 12.18B | 12.44B | 12.95B | 11.00B | 11.36B | 9.71B | 9.07B | 9.01B | 10.11B | 8.41B | 7.35B | 7.02B | 6.26B | 5.49B | 5.28B | 4.50B | 4.40B | 3.82B | 3.50B | 2.99B | 2.75B | 2.46B | 1.94B | 1.62B |
| Cost & Expenses | 57.16B | 41.00B | 35.51B | 35.97B | 34.60B | 33.36B | 32.59B | 30.85B | 31.95B | 35.55B | 36.37B | 37.39B | 39.07B | 42.63B | 23.41B | 17.76B | 18.58B | 18.95B | 16.15B | 16.32B | 14.03B | 42.12B | 37.99B | 31.27B | 25.12B | 20.52B | 17.97B | 14.84B | 12.28B | 10.56B | 6.61B | 6.17B | 5.49B | 5.02B | 4.31B | 4.07B | 3.69B | 3.09B | 2.71B |
| Interest Income | 365.00M | 157.00M | 36.00M | 59.00M | 274.00M | 343.00M | 385.00M | 328.00M | 289.00M | 266.00M | 264.00M | 232.00M | 199.00M | 83.00M | 210.20M | 631.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.15B | 962.00M | 806.00M | 831.00M | 893.00M | 772.00M | 754.00M | 693.00M | 672.00M | 732.00M | 801.00M | 714.00M | 749.00M | 715.00M | 458.00M | 251.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.87B | 3.91B | 3.21B | 3.49B | 3.65B | 4.52B | 4.64B | 5.44B | 6.38B | 6.69B | 6.99B | 6.98B | 7.43B | 7.38B | 2.58B | 1.63B | 1.99B | 2.27B | 1.71B | 1.45B | 1.31B | 1.49B | 1.46B | 1.28B | 1.14B | 1.02B | 1.03B | 927.10M | 859.20M | 875.50M | 414.70M | 321.40M | 263.80M | 254.00M | 221.70M | 204.90M | 210.00M | 193.90M | 182.50M |
| EBITDA | 6.91B | 21.32B | 17.90B | 10.18B | 16.01B | 13.99B | 11.95B | 10.79B | 12.45B | 24.71B | 13.33B | 16.43B | 15.51B | 9.75B | 18.33B | 11.81B | 13.06B | 5.98B | 7.75B | 7.58B | 9.44B | 11.07B | 10.94B | 9.63B | 7.54B | 5.27B | 5.64B | 5.07B | 4.68B | 5.05B | 4.95B | 3.74B | 3.32B | 2.86B | 2.41B | 2.07B | 1.54B | 1.13B | 936.90M |
| EBITDA Ratio | 11.49% | 39.32% | 34.73% | 23.03% | 27.50% | 24.24% | 20.60% | 22.65% | 20.18% | 45.48% | 18.95% | 22.84% | 20.37% | 24.80% | -18.28% | 28.56% | 53.99% | 26.43% | 35.22% | 33.05% | 41.98% | 21.37% | 22.92% | 23.85% | 23.05% | 19.58% | 23.88% | 25.58% | 28.05% | 33.75% | 47.14% | 38.71% | 38.55% | 37.25% | 36.81% | 34.81% | 30.49% | 27.47% | 26.41% |
| Operating Income | 2.95B | 19.40B | 13.70B | 6.08B | 9.23B | 5.73B | 3.63B | 3.58B | 1.59B | 12.52B | 1.36B | 3.82B | 2.36B | 4.03B | -7.59B | 5.18B | 11.08B | 3.71B | 6.04B | 6.13B | 8.13B | 9.58B | 9.47B | 8.35B | 6.39B | 4.25B | 4.61B | 4.15B | 3.82B | 4.18B | 4.53B | 3.42B | 3.05B | 2.60B | 2.19B | 1.86B | 1.33B | 940.20M | 754.40M |
| Operating Income Ratio | 4.91% | 32.72% | 28.14% | 14.63% | 19.70% | 13.55% | 9.04% | 8.98% | 4.04% | 29.64% | 3.08% | 8.08% | 4.91% | 8.75% | -27.67% | 21.72% | 45.77% | 16.41% | 27.46% | 26.73% | 36.14% | 18.50% | 19.86% | 20.69% | 19.55% | 15.80% | 19.50% | 20.91% | 22.90% | 27.90% | 43.19% | 35.39% | 35.49% | 33.94% | 33.43% | 31.36% | 26.34% | 22.77% | 21.27% |
| Total Other Income/Expenses | -1.07B | -1.84B | 680.00M | 315.00M | 3.54B | -230.00M | -986.00M | 1.08B | -2.15B | 4.77B | -2.12B | -1.14B | -1.64B | -1.70B | 11.27B | 3.85B | -2.25B | 2.63B | 1.44B | 530.90M | 926.30M | 632.60M | 927.90M | 735.00M | 2.23B | 3.88B | 1.85B | 1.40B | 977.80M | 238.00M | -783.00M | 144.20M | 114.00M | 94.80M | 93.40M | 8.40M | 72.00M | 133.10M | 102.60M |
| Income Before Tax | 1.89B | 16.44B | 13.88B | 8.79B | 11.46B | 8.70B | 6.75B | 7.50B | 5.40B | 17.28B | 5.55B | 9.23B | 7.33B | 1.65B | 15.29B | 9.81B | 3.37B | 6.22B | 7.36B | 7.97B | 9.05B | 10.21B | 10.40B | 9.82B | 8.62B | 8.13B | 6.46B | 5.54B | 4.80B | 4.42B | 3.10B | 3.56B | 3.17B | 2.70B | 2.28B | 1.87B | 1.41B | 1.07B | 857.00M |
| Income Before Tax Ratio | 3.14% | 27.74% | 28.50% | 21.17% | 24.47% | 20.57% | 16.82% | 18.84% | 13.67% | 40.92% | 12.59% | 19.53% | 15.26% | 3.59% | 55.75% | 41.12% | 13.93% | 27.48% | 33.45% | 34.76% | 40.25% | 19.72% | 21.80% | 24.34% | 26.35% | 30.24% | 27.34% | 27.94% | 28.76% | 29.49% | 29.55% | 36.88% | 36.81% | 35.18% | 34.85% | 31.50% | 27.76% | 25.99% | 24.16% |
| Income Tax Expense | 1.51B | 1.92B | 1.52B | 1.71B | 1.69B | 2.51B | 4.16B | 1.79B | 942.00M | 5.35B | 1.03B | 2.44B | 942.00M | 671.00M | 2.27B | 2.00B | 95.30M | 1.79B | 2.73B | 2.16B | 2.46B | 3.06B | 3.12B | 3.00B | 2.73B | 2.88B | 1.85B | 1.66B | 1.46B | 1.42B | 936.50M | 1.12B | 1.05B | 917.60M | 787.60M | 664.20M | 498.80M | 397.60M | 317.10M |
| Net Income | 365.00M | 14.52B | 13.05B | 7.07B | 9.84B | 6.22B | 2.57B | 5.69B | 4.44B | 11.92B | 4.40B | 6.66B | 6.27B | 861.00M | 12.90B | 7.81B | 3.28B | 4.43B | 4.63B | 5.81B | 6.83B | 7.15B | 7.28B | 6.82B | 5.89B | 5.25B | 4.61B | 3.88B | 3.34B | 3.00B | 2.17B | 1.98B | 2.12B | 1.78B | 1.50B | 1.21B | 906.40M | 675.70M | 539.90M |
| Net Income Ratio | 0.61% | 24.49% | 26.79% | 17.02% | 21.01% | 14.71% | 6.40% | 14.30% | 11.25% | 28.22% | 10.00% | 14.09% | 13.05% | 1.87% | 47.04% | 32.74% | 13.54% | 19.59% | 21.04% | 25.34% | 30.38% | 13.80% | 15.26% | 16.90% | 18.01% | 19.51% | 19.52% | 19.57% | 19.99% | 20.02% | 20.63% | 20.54% | 24.66% | 23.22% | 22.83% | 20.32% | 17.91% | 16.37% | 15.22% |
| EPS | 0.14 | 5.73 | 5.16 | 2.79 | 3.84 | 2.40 | 0.95 | 2.07 | 1.60 | 4.20 | 1.50 | 2.20 | 2.06 | 0.28 | 4.15 | 3.65 | -1.04 | 2.04 | 2.11 | 2.63 | 2.97 | 3.17 | 3.18 | 2.96 | 2.51 | 2.21 | 1.92 | 1.60 | 1.35 | 1.19 | 0.94 | 1.06 | 0.92 | 0.76 | 0.63 | 0.51 | 0.37 | 0.27 | 0.21 |
| EPS Diluted | 0.14 | 5.71 | 5.14 | 2.78 | 3.82 | 2.32 | 0.93 | 2.04 | 1.56 | 4.07 | 1.47 | 2.16 | 2.02 | 0.28 | 4.15 | 3.63 | -1.04 | 2.03 | 2.10 | 2.62 | 2.97 | 3.14 | 3.14 | 2.90 | 2.45 | 2.15 | 1.87 | 1.56 | 1.32 | 1.18 | 0.93 | 1.05 | 0.91 | 0.76 | 0.63 | 0.51 | 0.37 | 0.27 | 0.21 |
| Weighted Avg Shares Out | 2.61B | 2.53B | 2.53B | 2.53B | 2.57B | 2.59B | 2.70B | 2.75B | 2.78B | 2.84B | 2.93B | 3.03B | 3.04B | 3.10B | 2.11B | 2.14B | 2.17B | 2.18B | 2.20B | 2.22B | 2.24B | 2.26B | 2.29B | 2.31B | 2.35B | 2.37B | 2.40B | 2.43B | 2.47B | 2.51B | 2.30B | 1.87B | 2.31B | 2.34B | 2.37B | 2.37B | 2.45B | 2.50B | 2.57B |
| Weighted Avg Shares Out (Dil) | 2.55B | 2.54B | 2.54B | 2.54B | 2.58B | 2.68B | 2.75B | 2.79B | 2.84B | 2.93B | 3.00B | 3.08B | 3.09B | 3.12B | 2.27B | 2.14B | 2.19B | 2.19B | 2.20B | 2.23B | 2.25B | 2.28B | 2.32B | 2.35B | 2.40B | 2.44B | 2.47B | 2.49B | 2.54B | 2.55B | 2.33B | 1.89B | 2.33B | 2.34B | 2.37B | 2.37B | 2.45B | 2.50B | 2.57B |
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday.
Modifi Biosciences Acquired by Merck
Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers
Merck (MRK) Advances While Market Declines: Some Information for Investors
Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close.
3 Attractive Biotechs With Recent Positives
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against...
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.
Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from a Phase 2 clinical study evaluating the investigational combination of...
Merck RSV jab has the potential to protect infants
Merck & Co Inc's (NYSE:MRK, ETR:6MK) experimental treatment for respiratory syncytial virus (RSV) has shown positive results in a mid- to late-stage trial, moving the company closer to seeking regulatory approval. The treatment, clesrovimab, aims to protect infants from RSV,...
Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants.
Source: https://incomestatements.info
Category: Stock Reports